Product Introduction:

This product is used for the detection of 14 types of high-risk HPV, which cause cervical cancer. It has clinical significance for guidance when screening the high-risk population with cervical precancerous lesions. The 14 high-risk HPV types, as classified by WHO, that this product detects are: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.

【Product advantages】

1. No special requirements for experimental conditions

The test kit adopts a hybridization capture-chemiluminescence method, which does not require nucleic acid extraction and amplification. The product is suitable for use in hospitals of all levels to carry out detection in-house. There is no specific need for an external gene amplification laboratory.

2. Avoids false negative results

- The use of 14 types of RNA probes avoids false negative results that may arise due to missing HPV L1 region

- The product does not require DNA extraction, avoiding false negatives due to extraction loss

- The negative predictive value is >99.9%

- Excellent repeatability of test results

3. Avoids false positive results

- The product does not require nucleic acid amplification, effectively avoiding false positives caused by environmental factors

- The WHO recommended cut-off value (1.0pg/mL) ensures high specificity for identifying high-grade cervical intraepithelial neoplasia (CIN)

- There is no cross-reactivity with low-risk HPV, ensuring that positive results are associated with clinical lesions

Package specifications: 48 tests/box, 96 tests/box

Storage conditions: 2~8℃, avoid freezing

Validity period: 12 months